非布司他的用法用量

Febuxostat is a xanthine oxidase (XO) inhibitor that can selectively inhibit xanthine oxidase, reduce uric acid production and lower blood uric acid levels. It was developed by Teijin Company of Japan. Its indication is to treat hyperuricemia (gout). In 2009, the U.S. Food and Drug Administration (FDA) approved febuxostat, also known as febuxostat, feburic.

The effectiveness of febuxostat in the general population is approximately 70%, which is higher than that of allopurinol. and significantly higher than the placebo group. Clinical trial data on more than 3,000 people show that febuxostat can effectively reduce uric acid in the blood to 360 μmol/L after taking the drug for six months.

To achieve the therapeutic effect of febuxostat, correct usage and dosage are essential.

Under normal circumstances, the initial recommended dose of febuxostat (febuxostat, feburic) for patients is 40 mg/day, taken orally. If the symptoms are severe, it can be adjusted to 80 mg/day; if the serum uric acid level is still higher than 6 mg/dL after taking 40 mg/day for 2 weeks, the dose can be increased to 80 mg/day.

Dose adjustment: No dosage adjustment is required for patients with mild to moderate (CrCl 30-89 mL/min) renal impairment; the dosage for patients with severe (CrCl <30 mL/min) should not exceed 40 mg/day. No dose adjustment is required for patients with mild to moderate (Child-Pugh Class A or B) hepatic impairment; there are no trial data for patients with severe (Child-Pugh Class C) hepatic impairment and should be used with caution.

In the early stages of taking febuxostat (febuxostat, feburic), due to the rapid decline in serum uric acid concentration, uric acid deposited in tissues can be mobilized. To avoid this, nonsteroidal anti-inflammatory drugs or colchicine can be used for preventive administration.